Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Public ClinicalTrials.gov record NCT05361668. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects With Carcinoid Syndrome
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment in subjects with carcinoid syndrome. This study consists of a Randomized Treatment Phase followed by an Open-Label Extension (OLE) Phase.
Study identification
- NCT ID
- NCT05361668
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 36 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 22, 2022 (Actual)
- Primary completion
- Mar 7, 2024 (Actual)
- Completion
- Feb 24, 2026 (Actual)
- Last update posted
- Mar 19, 2026
2022 – 2026
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Crinetics Study Site | Los Angeles | California | 90048 | — |
| Crinetics Study Site | Los Angeles | California | 90095 | — |
| Crinetics Study Site | Newport Beach | California | 92663 | — |
| Crinetics Study Site | Stanford | California | 94305 | — |
| Crinetics Study Site | Miami | Florida | 33136 | — |
| Crinetics Study Site | Iowa City | Iowa | 52242 | — |
| Crinetics Study Site | Lexington | Kentucky | 40506 | — |
| Crinetics Study Site | New Orleans | Louisiana | 70112 | — |
| Crinetics Study Site | Boston | Massachusetts | 02118 | — |
| Crinetics Study Site | Rochester | Minnesota | 55905 | — |
| Crinetics Study Site | New York | New York | 10029 | — |
| Crinetics Study Site | Stony Brook | New York | 11794 | — |
| Crinetics Study Site | Cleveland | Ohio | 44106 | — |
| Crinetics Study Site | Columbus | Ohio | 43210 | — |
| Crinetics Study Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05361668, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 19, 2026 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05361668 live on ClinicalTrials.gov.